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Quality (AHRQ) comparative effectiveness report on treatments for seasonal aller-
gic rhinitis, which used a non-anchor based approach. Results: Using the most 
conservative estimates provided within the approved prescribing information, the 
change in rTNSS from baseline was -1.18 (p = 0.02) for azelastine hydrochloride, 
-1.35 (p = 0.014) for ciclesonide, -1.47 (p < 0.001) for fluticasone furoate, and -2.7* 
for MP29-02†(p < 0.001). Direct anchor-based estimates of MCID derived by Barnes 
and colleagues ranged from 0.28 units (95% CI: -0.18 to 0.73) and 0.23 units (95% 
CI: -0.16 to 0.62). Comparison of the anchor-based MCID threshold to the observed 
treatment indicates a positive clinical benefit for each treatment option. In con-
trast, the AHRQ report concluded that treatment options were equivalent to each 
other, to intranasal corticosteroids and to placebo, in contrast to common patient 
beliefs. ConClusions: Anchor based methods are critical in evaluating MCID as 
demonstrated by comparison of outcomes across intranasal products for seasonal 
allergic rhinitis. MCID methods need to be considered when evaluating evidence 
for health technology assessments. * Range of rTNSS is 0-12; 0-24 for MP29-02 † 
Dymista® = US trade name of MP29-02
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objeCtives: It is well established that translations of patient-reported outcome 
(PRO) measures need to be linguistically validated for the country or countries they 
will be used in - whether that means adapting an existing language version for 
use in a new country, or developing a language version for multiple countries from 
the beginning. While it is generally agreed that adaptations must be validated for 
their target countries, we aim to illustrate to stakeholders that there is more to 
this process than just a box-ticking exercise, by exploring the country-specific dif-
ferences that affect translations of PRO measures, and the implications they may 
have for the resulting patient data. Methods: We analysed examples from nearly 
ten years of in-house projects involving the adaptation of existing language ver-
sions for new target countries. A range of wording changes within these adaptation 
projects were identified and categorised according to their nature (linguistic varia-
tions or culturally-bound terms) and their position in the PRO (instruction, item or 
response option). We then further assessed the significance of each change and the 
possible impact on the respondent’s understanding of the measure and their ability 
to answer the items meaningfully. Results: The results of the two-part analysis 
illustrate that although many differences between country-specific language ver-
sions may be considered inconsequential (i.e. if a UK spelling of an English word 
is used in the US, it may still be understood), depending on the type of linguistic 
variation and its prominence within the PRO itself, in some cases there is a real 
risk that without the change an item may be misinterpreted or even impossible to 
answer. ConClusions: The evidence provided by the linguistic and culturally-
bound changes made during in-country adaptation projects emphasises why the 
process of adapting a measure to its target country is invaluable for its successful 
administration.
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objeCtives: validation of the psychometric properties of the “vitality quotient” 
questionnaire (VQ) i.e. the measures of its internal consistency, external validation 
and sensitivity to change. Methods: Prospective observational survey on patients 
consulting for fatigue and taking Bion3® during winter . The VQ includes 10 ques-
tions describing subjects’ activities and mood, rated from “1: very often” to “10: 
never”. Its comprehensibility and test-retest reliability has been evaluated in one 
other study. Each patient fulfil the VQ and the Pichot scale which is a reference scale 
for fatigue evaluation at inclusion and every month during three months. Internal 
consistency of the QV was measured with Cronbach’s alpha coefficient, external 
validation by its correlation coefficient with Pichot scale and its sensitivity to change 
by the paired T test of its average variations during the study period. Results: 132 
subjects 48.2 ± 13.5 years old (63.6% women) were followed. The Cronbach’s alpha 
coefficient has a very high level of 0.93 and therefore indicates a very good internal 
consistency. The study of the VQ correlation with the fatigue scale of Pichot at 
baseline shows a high Pearson coefficient of r = -0.67 (p < 0.0001) and the study of 
the correlation of their changes during the three months is of r = -0.75 (p < 0.0001). 
The QV is also sensitive to change. After one month the VQ increases from 47.3 ± 
18.5 to 60.4 ± 20.5 and then to 73.5 ± 18.0 after 2 months and to 80.9 ± 18.1 after 3 
months which is highly significant (p< 0,0001) and corresponds to improvements of 
respectively +27.7%, +55.4% and +71.0% of the initial vitality of the subjects taking 
Bion3®. ConClusions: This study validates psychometrics properties (reliability, 
external validity and sensitivity to change) of the « vitality quotient » which appears 
an effective to evaluate food supplements effects in healthy subjects complaining 
of fatigue and expressing a loss of vitality.
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objeCtives: (1) To investigate the difficulties experienced during translation of 
Clinical Outcomes Assessments for South Africa with regard to the existence of mul-
tiple official languages (2) To identify patterns of terminology usage across different 
settings in South Africa Methods: Back translation and cognitive debriefing reviews 
were reviewed across multiple South African languages from linguistic validation 
projects. The results were compared and challenges with conceptual equivalence 
impacts were described as difficulty standing from a seated position or using stairs 
in early disease followed by increased falls, gait impairment, and progressive loss of 
ambulation resulting in the need for assistive devices. Upper extremity weakness 
results in difficulty with activities requiring gripping and lifting. Dysphagia can 
include swallowing difficulties, choking, and interference with nutritional intake. 
Psychosocial impacts were often related to the loss of autonomy, fear of falls, social 
and familial impacts and the need for assistance. ConClusions: This sIBM disease 
model adds significantly to the literature describing the patient impact of sIBM and 
may be used to guide selection of clinical trial endpoints.
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objeCtives: To evaluate health-related quality of life (HRQoL) of End Stage Renal 
Failure (ESRF) patients in Pakistan. Methods: A prospective cross-sectional study 
was conducted at a tertiary care hospital in a province of Pakistan, the Punjab. 
WHOQOL-BREF (Urdu version, pretested for reliability and validity) was used as 
research instrument. Data was obtained through face-to-face interviews and where 
possible by gender-based focus group sessions. WHOQOL-BREF score was obtained 
and evaluated to determine HRQoL of ESRF patients. Patients were also asked 
to share their personal experiences of being diagnosed and treatment given. All 
obtained data were analyzed using descriptive and inferential statistics by using 
SPSS 20.0. Results: The overall Cronbach’s alpha coefficient of the revalidated 
WHOQOL-BREF questionnaire was 0.799. The scores for negative feelings, depres-
sion, living place, personal relationships and sexual life were significantly different 
in the psychological health and social relations domains. Mean age, gender, educa-
tion level, occupation and physical exercise were also significantly associated with 
the HRQoL of the ESRF patients. ConClusions: The WHOQOL-BREF was a reliable 
and valid research tool to evaluate HRQoL of ESRF patients in Pakistan. A significant 
impact on HRQoL of the ESRF patients was observed. Together with curative and pre-
ventative measures, there is also a great need to measure HRQoL of ESRF patients.
PRM109
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objeCtives: The Conners 3rd Edition–Parent (Conners 3–P) is used to obtain par-
ents’ observations about the behaviors and feelings of children and adolescents 
aged 6-18 years old. Developed in American English and published by Multi-Health 
Systems, it was designed to assess Attention Deficit/Hyperactivity Disorder 
(ADHD). The short version provides the evaluation of inattention, hyperactivity/
impulsivity, learning problems, executive functioning, aggression, and peer rela-
tions, and includes 43 items rated on a 4-point scale (“Not true at all” to “Very 
much true”). The objective of this study is to present the challenges faced during 
the translation of the instrument into ten Indo-European languages (English for 
four countries, French, Italian, German, Spanish for three countries), one Sino-
Tibetan (Chinese), and one Austronesian language (Malay). Methods: The fol-
lowing translation method was used: 1. Concept definition; 2. Forward/backward 
translation [or adaptation for English and Spanish versions (i.e., for Argentina 
and Mexico)]; 3. Review of the back-translations/adaptations by the copyright 
holder of the instrument; and 4. Cognitive interviews with five parents in each 
country. Results: The translation process did not reveal any cultural issues since 
most of the concepts assessed were cross-culturally relevant. The main difficul-
ties consisted in finding conceptual equivalents of the original items with strong 
idiomatic content. For instance, the most challenging items were items 13 (“Acts 
as if driven by a motor”), 31 (“Tells the truth; doesn’t even tell “little white lies.”), 
and 40 (“Behaves like an angel”). Most of the solutions were found using concept 
definitions. Parents were important in discussing changes or proposing solu-
tions. Examples will be provided. ConClusions: The multi-step process proved 
to be critical to ensure the production of conceptually equivalent and culturally 
appropriate translations of the Conners 3–P into Indo-European, Sino-Tibetan and 
Austronesian languages. The involvement of the copyright holder and of parents 
was crucial in finding solutions.
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objeCtives: Anchor based methods are commonly used to derive MCID in treat-
ment assessments. The objective of this work was to compare the outcomes of 
an anchor-based vs. non-anchor based methodology in the health technology 
assessment of intranasal allergic rhinitis treatments. Methods: Data specific to 
the treatment benefit (active drug versus vehicle placebo) of 4 intranasal seasonal 
allergic rhinitis treatments (azelastine hydrochloride, ciclesonide, fluticasone furo-
ate, MP29-02) using the reflective Total Nasal Symptom Score (rTNSS) were obtained 
from the FDA approved prescribing information. Anchor-based MCID estimates 
reported from Barnes et al. 2010 were then compared to the treatment effect. The 
outcomes were then compared to the July 2013 Agency for Healthcare Research & 
